We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EHC icon
126
Encompass Health
EHC
$11.2B
$794K 0.01%
+11,900
New +$771K
PTGX icon
127
Protagonist Therapeutics
PTGX
$8.75B
$688K 0.01%
30,000
– –
PFE icon
128
Pfizer
PFE
$140B
$658K 0.01%
22,868
+13,313
+139% +$402K
VRDN icon
129
Viridian Therapeutics
VRDN
$2.13B
$653K 0.01%
30,000
-33,770
-53% -$533K
RCKT icon
130
Rocket Pharmaceuticals
RCKT
$348M
$629K 0.01%
+21,000
New +$463K
MRUS
131
DELISTED
Merus
MRUS
$624K 0.01%
22,700
-21,800
-49% -$509K
DVAX
132
DELISTED
Dynavax Technologies
DVAX
$604K 0.01%
43,200
-40,000
-48% -$556K
VERV
133
DELISTED
Verve Therapeutics
VERV
$544K 0.01%
+39,000
New +$483K
XOP icon
134
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.42B
$534K 0.01%
3,900
– –
GPCR icon
135
Structure Therapeutics
GPCR
$3.49B
$501K 0.01%
12,300
-4,500
-27% -$258K
SUPN icon
136
Supernus Pharmaceuticals
SUPN
$2.68B
$437K 0.01%
15,100
-565,500
-97% -$15M
DVA icon
137
DaVita
DVA
$15.1B
$398K 0.01%
+3,800
New +$351K
LULU icon
138
lululemon athletica
LULU
$13B
$394K 0.01%
+770
New +$333K
LTH icon
139
Life Time Group Holdings
LTH
$9.42B
$380K 0.01%
+25,200
New +$362K
NKE icon
140
Nike
NKE
$61.9B
$369K 0.01%
+3,400
New +$365K
BMEA icon
141
Biomea Fusion
BMEA
$90.4M
$363K 0.01%
+25,000
New +$304K
BCYC
142
Bicycle Therapeutics
BCYC
$270M
$362K 0.01%
20,000
-19,200
-49% -$318K
CAH icon
143
Cardinal Health
CAH
$53.4B
$353K 0.01%
+3,500
New +$347K
CCCC icon
144
C4 Therapeutics
CCCC
$376M
$350K 0.01%
+62,000
New +$141K
WW
145
DELISTED
WW International
WW
$350K 0.01%
+40,000
New +$340K
VKTX icon
146
Viking Therapeutics
VKTX
$4.04B
$326K 0.01%
+17,500
New +$229K
AUTL
147
Autolus Therapeutics
AUTL
$386M
$322K ﹤0.01%
+50,000
New +$191K
ETNB
148
DELISTED
89bio
ETNB
$226K ﹤0.01%
20,200
-19,000
-48% -$175K
VTRS icon
149
Viatris
VTRS
$20.1B
$195K ﹤0.01%
18,003
-158,845
-90% -$1.52M
GDXJ icon
150
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
$190K ﹤0.01%
5,000
– –
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.